Is Indrapr.Medical overvalued or undervalued?

As of 7 November 2025, Indrapr.Medical's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company appears to be undervalued based on its current metrics. Key ratios include a PE Ratio of 32.48, an EV to EBITDA of 4.32, and a Price to Book Value of 0.86, which suggest that the stock is trading at a reasonable valuation compared to its earnings and asset base.
In comparison with peers, Indrapr.Medical's PE Ratio of 32.48 is significantly lower than Apollo Hospitals' 65.65 and Max Healthcare's 91.69, indicating a more attractive valuation relative to these competitors. Additionally, the company has shown strong performance with a year-to-date return of 18.41%, outperforming the Sensex's 6.50% during the same period, reinforcing the notion that it may be undervalued in the current market.